The efficacy of prostaglandin E1 as a pharmacological treatment of erectile dysfunction (impotence) was compared with the standard treatment, papaverine, in a single blind, crossover trial. A total of 129 impotent men received intracavernous injections of either prostaglandin E1 (5 micrograms) or papaverine (18 mg.) 1 month apart. Observations by 1 observer recorded 10 to 20 minutes after injection demonstrated that prostaglandin E1 generated a better erection in 72 men (55.8%) compared to papaverine. Papaverine was more effective than prostaglandin E1 in 23 men (17.8%, chi-square 6.26, p less than 0.025). Subjective assessment by the patients who detected a difference showed that 71 (55%) preferred prostaglandin E1 and 35 (27%) preferred papaverine (chi-square 11.56, p less than 0.001). A total of 34 men achieved full erections with prostaglandin E1 compared to 17 who used papaverine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-5347(17)39864-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is the phoenix sign phenomenon due to vasodilation? A double-blinded, randomized controlled trial comparing motor function recovery after diagnostic common fibular nerve block with lidocaine and papaverine.
BMC Musculoskelet Disord
October 2024
NE Wyoming Wound Care Clinic, Sheridan, WY, USA.
Article Synopsis
- Focal entrapment of the common fibular nerve (CFN) is a common issue in the lower body that can be hard to diagnose, with a temporary strengthening response known as the "Phoenix sign" sometimes observed after lidocaine blocks.
- A study involving 20 patients tested the effects of two vasodilating agents, lidocaine and papaverine, on improving muscle strength in the anterior compartment by measuring the extensor hallucis longus (EHL) muscle before and after treatment.
- Results showed that both agents produced significant improvements in muscle strength without notable differences between them, suggesting the Phoenix Effect is likely due to improved local blood circulation.
Effects of Papaverine on Experimentally Induced Myringosclerosis.
J Craniofac Surg
October 2024
Department of Medical Pathology, İzmir Faculty of Medicine, University of Health Sciences Turkey, İzmir, Türkiye.
Article Synopsis
- The study investigates how papaverine affects myringosclerosis (MS) in rats, focusing on its impact on hearing issues caused by the condition.
- Twenty Wistar albino rats were divided into four groups to test different treatments, including myringotomy, saline application, and both systemic and topical papaverine.
- Results indicated that papaverine increased the severity of MS, possibly due to its vasodilating effects that lead to higher levels of oxygen-derived free radicals, warranting further evaluation of its implications on MS.
The Effect of Local Papaverine Use in an Experimental High-Risk Colonic Anastomosis Model: Reduced Inflammatory Findings and Less Necrosis.
J Clin Med
September 2024
Department of Gastroenterology Surgery, Private Office, 06560 Ankara, Turkey.
To assess the impact of topical papaverine administration in complete and incomplete colonic anastomosis, by examining bursting pressure, hydroxyproline concentration, collagen content, inflammation levels, inflammatory cell infiltration, neoangiogenesis, and necrosis grades. We performed an experimental study on rats, in which they were divided into the following 4 groups of 16 subjects each. Group 1 [complete anastomosis (CA) without papaverine (CA -P) group], Group 2 [CA with papaverine (CA +P) group], Group 3 [incomplete anastomosis (ICA) without papaverine (ICA -P) group], and Group 4 [ICA with papaverine (ICA +P) group].
View Article and Find Full Text PDFInvestigation of Cissus populnea as a Potential Therapeutic Agent for Erectile Dysfunction.
Cell Biochem Biophys
August 2024
Bioinformatics and Molecular Biology Unit, Department of Biochemistry, Federal University of Technology, Akure, Ondo State, Nigeria.
Article Synopsis
- * Extracts from CP were tested on rats with paroxetine-induced erectile dysfunction, revealing that CP reduces PDE5 activity while increasing the expression of beneficial genes related to erections.
- * Several compounds from CP displayed superior docking scores and favorable properties for inhibiting PDE5 compared to sildenafil, suggesting that CP could be a viable alternative for treating erectile dysfunction and merits more research.
Unveiling the science behind erectile dysfunction topical therapy: investigating transdermal papaverine as a novel treatment approach.
Sex Med Rev
September 2024
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Introduction: Erectile dysfunction is among the most prevalent urologic issues affecting men globally and is characterized by a high incidence rate. This condition significantly affects the quality of life of patients and their sexual partners.
Objectives: Due to the interactions, contraindications, and side effects associated with systemic drugs, recent research has increasingly focused on topical and transdermal medications for the treatment of erectile dysfunction.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!